N-[(2R)-2-{[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide
Star1
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- N-[(2R)-2-{[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide
- DrugBank Accession Number
- DB08310
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 359.4195
Monoisotopic: 359.184506303 - Chemical Formula
- C19H25N3O4
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UPeptide deformylase Not Available Mycobacterium tuberculosis - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Beta amino acids and derivatives
- Alternative Parents
- Benzoxazoles / N-acylpyrrolidines / Benzenoids / Tertiary carboxylic acid amides / Oxazoles / Heteroaromatic compounds / Hydroxamic acids / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds show 4 more
- Substituents
- Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzoxazole / Beta amino acid or derivatives / Carbonyl group / Carboxamide group / Heteroaromatic compound / Hydrocarbon derivative show 13 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- QDDZLTVSNABZIK-ZBFHGGJFSA-N
- InChI
- InChI=1S/C19H25N3O4/c1-2-3-7-14(12-21(25)13-23)19(24)22-11-6-9-16(22)18-20-15-8-4-5-10-17(15)26-18/h4-5,8,10,13-14,16,25H,2-3,6-7,9,11-12H2,1H3/t14-,16+/m1/s1
- IUPAC Name
- N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-butyl-3-oxopropyl]-N-hydroxyformamide
- SMILES
- [H][C@@](CCCC)(CN(O)C=O)C(=O)N1CCC[C@@]1([H])C1=NC2=C(O1)C=CC=C2
References
- General References
- Not Available
- External Links
- PubChem Compound
- 25134267
- PubChem Substance
- 99444781
- ChemSpider
- 24712637
- BindingDB
- 50255030
- ChEMBL
- CHEMBL506649
- ZINC
- ZINC000040980708
- PDBe Ligand
- NVC
- PDB Entries
- 3e3u
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.16 mg/mL ALOGPS logP 2.58 ALOGPS logP 2.14 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 8.39 Chemaxon pKa (Strongest Basic) -0.37 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 86.88 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 95.3 m3·mol-1 Chemaxon Polarizability 38.87 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.535 Caco-2 permeable - 0.6711 P-glycoprotein substrate Substrate 0.6451 P-glycoprotein inhibitor I Non-inhibitor 0.5502 P-glycoprotein inhibitor II Non-inhibitor 0.6674 Renal organic cation transporter Non-inhibitor 0.8714 CYP450 2C9 substrate Non-substrate 0.8291 CYP450 2D6 substrate Non-substrate 0.8052 CYP450 3A4 substrate Substrate 0.5781 CYP450 1A2 substrate Non-inhibitor 0.742 CYP450 2C9 inhibitor Non-inhibitor 0.6193 CYP450 2D6 inhibitor Non-inhibitor 0.9067 CYP450 2C19 inhibitor Non-inhibitor 0.545 CYP450 3A4 inhibitor Non-inhibitor 0.5974 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5511 Ames test Non AMES toxic 0.5169 Carcinogenicity Non-carcinogens 0.7118 Biodegradation Not ready biodegradable 0.9784 Rat acute toxicity 2.4451 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9477 hERG inhibition (predictor II) Non-inhibitor 0.7653
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-3bc86f62f2674524a8d2 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0019000000-b28316dc0ffef0c53683 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0532-3294000000-cf88d063bc4357df4e10 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-2009000000-3f988a73d43b55143b44 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00kf-9321000000-04ce807552adb88487e2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-06du-5941000000-954d7ae29fa4ee88d891 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 183.51274 predictedDeepCCS 1.0 (2019) [M+H]+ 186.02914 predictedDeepCCS 1.0 (2019) [M+Na]+ 194.25957 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsPeptide deformylase
- Kind
- Protein
- Organism
- Mycobacterium tuberculosis
- Pharmacological action
- Unknown
- General Function
- Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity).
- Specific Function
- metal ion binding
- Gene Name
- def
- Uniprot ID
- P9WIJ3
- Uniprot Name
- Peptide deformylase
- Molecular Weight
- 20938.52 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:30 / Updated at June 12, 2020 16:52